Bordeaux Métropole Awards Two New Markets to Plastic Omnium Environment

PARIS--(BUSINESS WIRE)--

Regulatory News:

Bordeaux Métropole (formerly CUB (Bordeaux Urban Community)) – which covers 28 towns and villages and 724,000 inhabitants – has awarded Plastic Omnium Environment (Paris: POM) two important markets for a four-year period.

The first market involves the supply of more than 140,000 wheeled waste collection containers for the collection of household waste and the selective recycling of waste.The second market, which has just been awarded, is the maintenance of waste equipment.

Plastic Omnium will provide these services from its service base at Mérignac, where ten people are employed.

About Plastic Omnium Environment:With sales in 2014 of €432 million and 2,000 employees worldwide, Plastic Omnium Environment supports local authorities in achieving their recycling objectives, provides reliable, aesthetic solutions which can be adapted to all types of environment, and offers equipment maintenance and upkeep services. To meet its customers' needs in an even more targeted way, Plastic Omnium is also developing IT solutions for the management of pre-collection and collection data.

Plastic Omnium is the worldwide leader in automotive body components and modules, and automotive fuel systems, as well as the world leader in waste removal containers for local authorities and businesses. The Group employs 22,000 people in 111 plants, 21 R&D centres and 30 countries. Plastic Omnium is listed on the Euronext Paris, Compartment A, and is part of the SRD and the SBF 120 and CAC Mid 60 indexes (ISIN Code: FR0000124570).

Plastic Omnium
Financial information
Tel: +33 (0)1 40 87 64 49
Fax: +33 (0)1 40 87 96 62
[email protected]

Source: Plastic Omnium

You May Also Be Interested In

• Man Group PLC : Form 8.3 - Tyman plc
• Spinergie's digital fleet management platform selected by Seaward Services for remote monitoring and performance optimization
• Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer